Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders.

PET imaging with [F-18]FDG has been used extensively for research and clinical applications in dementia. In the brain, [F-18]FDG accumulates around synapses and represents local neuronal activity. Patterns of altered [F-18]FDG uptake reflecting local neuronal dysfunction provide differential diagnostic clues for various dementing disorders. Image interpretation can be accomplished by employing statistical brain mapping techniques. Various guidelines have been published to support the appropriate use of [F-18]FDG PET for clinical dementia workup. PET images with [F-18]FDG demonstrate distinct patterns of decreased uptake for Alzheimer's disease (AD), Dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD) as well as its multiple subtypes such as behavioral variant FTD, primary progressive aphasia (PPA), progressive supranuclear palsy, and corticobasal degeneration to aid in the differential diagnoses. Mixed dementia, not only AD + Vascular Dementia, but also AD + other neurodegenerative disorders, should also be considered when interpreting [F-18]FDG PET images. Brain PET imaging with [F-18]FDG remains a valuable component of dementia workup owing to its relatively low cost, differential diagnostic performance, widespread availability, and physicians' experience over more than 40 years since the initial development.

Areolar-cutaneous "junction" injections to augment sentinel node count activity.

PURPOSE: The authors report on a modified lymphoscintigraphy protocol for increasing activity in the sentinel node (SN) through a specific technique (LymphoBoost). It consists of an areolar-cutaneous "junction" injection, using a very shallow, high-volume, high-specific-activity injection of 100% filtered Tc-99m sulfur colloid, as an adjunct to their standard protocol. MATERIALS AND METHODS: Results from a previously optimized protocol (group 1, n = 28) were compared with those from their new protocol (group 2, n = 85), which consisted of two sets of consecutively applied (within 12 to 20 minutes) injections: group 2A composed of perilesional and intradermal injections (similar to the previous group 1) followed by group 2B LymphoBoost injections within 12 to 20 minutes in the same patients. Regions of interest were drawn around the SN and the injection sites (IS) at the end of the studies to calculate the end-of-study SN:IS ratio for both group 1 and group 2 studies. The SN:IS ratio is generally independent of dose and is a measurement of the "efficiency" of getting activity from the IS to the SN. RESULTS: The mean SN:IS ratio in group 2 was 3.34 times greater than that in group 1 studies (P < 0.0005). The median SN:IS ratio was 3.53 times greater in the group 2 studies. Many cases showed a dramatic increase in SN counts before the LymphoBoost injection was even completed, with more than 5% of injected activity reaching nodes at the end of the study in some patients. Multiple different lymphatic pathways were noted, but all led to the same node(s). No significant disagreement between group 2A and group 2B results was noted. CONCLUSIONS: Areolar-cutaneous junction injections, performed under these conditions, augment SN activity dramatically in most patients. Hotter nodes provide several benefits, especially when next-day surgery is contemplated, and should also reduce the extent of dissection needed to remove the sentinel node.

Effect of high specific-activity sulfur colloid preparations on sentinel node count rates.

PURPOSE: Preliminary results by other investigators suggest that increasing the specific activity of Tc-99m nanocolloid preparations increases the measured counts in sentinel nodes compared with lower specific-activity (SA) preparations using the same initial injected dose. The authors set out to determine whether a similar result could be perceived with Tc-99m sulfur colloid (SC) preparations. METHODS: Twenty-three consecutive patients (low SA group) with successful visualization of sentinel nodes by lymphoscintigraphy before our standard protocol was changed to a higher SA preparation were compared with 28 patients (high SA group) just after the switch. Injection techniques were similar in both groups: peritumoral injections at two to four points of a mixture of half-filtered (0.22 microm filter) and unfiltered Tc-99m sulfur colloid in 6 ml followed immediately by intradermal injections of filtered sulfur colloid above the tumor. Activity levels for both types of injections ranged from 3.7 to 11.1 mBq (100 to 300 microCi). Preparation of the higher SA mixture of sulfur colloid was achieved by using only one eighth of the sulfur colloid vial contents when the same activity (125 mCi) of Tc-99 was added. Regions of interest were drawn around the images of sentinel nodes and the initial injection site in the anterior and lateral projections. Ratios of sentinel node to initial injection site count were calculated for both groups. RESULTS: The mean ratio of sentinel node to injection site count in the high SA group was 2.9 times greater than that in the low SA group. The median ratio value was 2.7 times greater in the high SA group. CONCLUSION: These preliminary results suggest higher counts in the sentinel node are possible with a higher SA preparation.